- Home
- PDM vs STOK Comparison
PDM vs STOK Comparison
Compare PDM & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDM
- STOK
- Stock Information
- Founded
- PDM 1997
- STOK 2014
- Country
- PDM United States
- STOK United States
- Employees
- PDM N/A
- STOK N/A
- Industry
- PDM Building operators
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- PDM Real Estate
- STOK Health Care
- Exchange
- PDM Nasdaq
- STOK Nasdaq
- Market Cap
- PDM 948.7M
- STOK 997.9M
- IPO Year
- PDM N/A
- STOK 2019
- Fundamental
- Price
- PDM $8.41
- STOK $19.76
- Analyst Decision
- PDM Buy
- STOK Strong Buy
- Analyst Count
- PDM 5
- STOK 6
- Target Price
- PDM $9.40
- STOK $26.60
- AVG Volume (30 Days)
- PDM 838.3K
- STOK 934.9K
- Earning Date
- PDM 10-23-2025
- STOK 08-12-2025
- Dividend Yield
- PDM 2.95%
- STOK N/A
- EPS Growth
- PDM N/A
- STOK N/A
- EPS
- PDM N/A
- STOK 0.91
- Revenue
- PDM $565,502,000.00
- STOK $199,893,000.00
- Revenue This Year
- PDM $0.09
- STOK $415.58
- Revenue Next Year
- PDM N/A
- STOK N/A
- P/E Ratio
- PDM N/A
- STOK $21.76
- Revenue Growth
- PDM N/A
- STOK 1218.82
- 52 Week Low
- PDM $5.46
- STOK $5.35
- 52 Week High
- PDM $11.12
- STOK $20.00
- Technical
- Relative Strength Index (RSI)
- PDM 69.47
- STOK 78.62
- Support Level
- PDM $8.04
- STOK $19.07
- Resistance Level
- PDM $8.41
- STOK $19.91
- Average True Range (ATR)
- PDM 0.18
- STOK 1.26
- MACD
- PDM 0.05
- STOK 0.14
- Stochastic Oscillator
- PDM 95.70
- STOK 96.55
About PDM Piedmont Office Realty Trust Inc.
Piedmont Realty Trust Inc is a fully integrated, self-managed real estate investment company focused on delivering an exceptional office environment. As an owner, manager, developer and operator of 16 MM SF of Class A properties across major U.S. Sunbelt markets, Piedmont Realty Trust is known for its hospitality-driven approach and commitment to transforming buildings into Piedmont PLACEs that enhance each client's workplace experience.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.